MGSHELL

Our goal arises from the need to solve the burdens associated with frequent injections for patients suffering from exudative maculopathy. The number of affected people increases dramatically and 40% of them do not follow the correct strategy and reach irreversible blindness. We offer the only solution able to replicate the current clinical practice without surgery, increasing patient compliance, decreasing healthcare costs and generating business for pharmaceutical companies.Le schede progetto sono disponibili in Area Riservata – sezione Area progetti”